why choose us

First received: June 06, 2023

Clinical Trial: Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Glioblastoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients With Surgically Resected Glioblastoma (GBM) or Astrocytoma With a Molecular Signature of Unmethylated Glioblastoma

Brief Summary: This study is an open-label, first-in-human, dose-escalation study of CV09050101 mRNA vaccine (CVGBM) in patients with newly diagnosed "MGMT-unmethylated" Glioblastoma (GBM).Patients with isocitrate dehydrogenase (IDH)-wildtype astrocytoma with a molecular signature of "unmethylated" GBM are also eligible.After surgical resection and completion of radiotherapy for GBM with or without chemotherapy, patients will receive CVGBM i.e. as monotherapy after radiotherapy with or without…

Read more